Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -313.46% is 115% below its 5-year average of -145.97%, around the middle of its 5-year range (-717.83%–-52.76%).
As of the fiscal period ended Tuesday, June 30, 2026. 27.92% above its 12-month average of -434.87%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -313.46%.
RETURN ON EQUITY (ROE)
-313.46%
RETURN ON EQUITY (ROE) AVG TTM
-434.87%
RETURN ON EQUITY (ROE) AVG 3Y
-199.35%
RETURN ON EQUITY (ROE) AVG 5Y
-145.97%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+27.92%
CURRENT VS 3Y AVG
-57.24%
CURRENT VS 5Y AVG
-114.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 698 covered companies
CURRENT VS SECTOR MEDIAN
-669.14%
vs the sector median at left
Quantum BioPharma Ltd.
Market Cap
$20.80M
Return on Equity (ROE)
-313.46%
TTM Avg
-434.87%
3Y Avg
-199.35%
5Y Avg
-145.97%
Market Cap
$20.23M
Return on Equity (ROE)
-351.86%
TTM Avg
-122.41%
3Y Avg
-86.06%
5Y Avg
-64.41%
Market Cap
$20.10M
Return on Equity (ROE)
-2067.81%
TTM Avg
-13234.78%
3Y Avg
-6645.16%
5Y Avg
-6645.16%
Market Cap
$19.67M
Return on Equity (ROE)
-136.36%
TTM Avg
-41.80%
3Y Avg
-1184.66%
5Y Avg
-795.29%
Market Cap
$21.84M
Return on Equity (ROE)
-260.37%
TTM Avg
-164.08%
3Y Avg
-188.26%
5Y Avg
-64.22%
Market Cap
$22.11M
Return on Equity (ROE)
-40.40%
TTM Avg
-55.95%
3Y Avg
-53.10%
5Y Avg
-83.38%
Market Cap
$22.36M
Return on Equity (ROE)
-421.06%
TTM Avg
-298.11%
3Y Avg
-181.82%
5Y Avg
-125.27%
Market Cap
$22.93M
Return on Equity (ROE)
-487.90%
TTM Avg
-205.19%
3Y Avg
-102.69%
5Y Avg
-68.50%
Market Cap
$18.65M
Return on Equity (ROE)
-75.34%
TTM Avg
-0.67%
3Y Avg
-77.39%
5Y Avg
-61.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $20.80M | -313.46% | -434.87% | -199.35% | -145.97% |
| NextCure, Inc. (NXTC)vs › | $20.23M | -351.86% | -122.41% | -86.06% | -64.41% |
| Actuate Therapeutics Inc (ACTU)vs › | $20.10M | -2067.81% | -13234.78% | -6645.16% | -6645.16% |
| P3 Health Partners Inc. (PIII)vs › | $19.67M | -136.36% | -41.80% | -1184.66% | -795.29% |
| Modular Medical, Inc. (MODD)vs › | $21.84M | -260.37% | -164.08% | -188.26% | -64.22% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | -40.40% | -55.95% | -53.10% | -83.38% |
| LeonaBio, Inc. (LONA)vs › | $22.36M | -421.06% | -298.11% | -181.82% | -125.27% |
| Rein Therapeutics Inc. (RNTX)vs › | $22.93M | -487.90% | -205.19% | -102.69% | -68.50% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | -75.34% | -0.67% | -77.39% | -61.36% |
| Cosmos Health Inc. (COSM)vs › | $17.79M | -117.98% | -84.94% | -64.05% | -76.29% |
ROE
-313.5%
ROA
-173.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -313.46% |
| 2025-12-31 | -378.70% |
| 2025-09-30 | -329.51% |
| 2025-06-30 | -717.83% |
| 2025-03-31 | -364.17% |
| 2024-12-31 | -123.71% |
| 2024-09-30 | -62.40% |
| 2024-06-30 | -67.51% |
| 2024-03-31 | -81.27% |
| 2023-12-31 | -134.71% |
| 2023-09-30 | -152.71% |
| 2023-06-30 | -184.74% |
| 2023-03-31 | -132.61% |
| 2022-12-31 | -77.29% |
| 2022-09-30 | -65.87% |
| 2022-06-30 | -52.76% |
| 2022-03-31 | -66.83% |
| 2021-12-31 | -65.19% |
| 2021-09-30 | -55.39% |
| 2021-06-30 | -64.70% |
| 2021-03-31 | -42.31% |
| 2020-12-31 | -70.78% |
| 2020-09-30 | -102.41% |
| 2020-06-30 | -130.14% |
| 2020-03-31 | -172.39% |
| 2019-12-31 | -114.18% |
| 2019-09-30 | -90.57% |
| 2019-06-30 | -50.62% |
| 2019-03-31 | -46.09% |
| 2018-12-31 | -48.00% |
